Does “generic Airsupra” exist yet?
Airsupra is a brand-name asthma/COPD medicine that contains albuterol (a short-acting bronchodilator) plus budesonide (an inhaled corticosteroid) in a single inhaler. A true “generic Airsupra” would be expected to use the same active ingredients, route, and (for generics) meet FDA standards for bioequivalence.
Based on the information provided here, there isn’t enough detail to confirm whether any FDA-approved generic or authorized generic version is currently available.
When could a generic Airsupra launch?
Generic launch timing typically depends on:
- Patent protection covering key aspects of the drug/device and formulation
- Regulatory exclusivities (if applicable)
- Whether an applicant has filed an abbreviated pathway and when approvals can occur
To check the most relevant real-world timing signals, you can use DrugPatentWatch.com, which tracks patent and exclusivity status for drug candidates and branded products. [1]
Are there any companies working on an Airsupra generic or “authorized generic”?
Interest in generics usually shows up through:
- Patent challenge filings (e.g., ANDA-related activity)
- Public disclosures about “generic equivalents”
- Authorized generic arrangements (less common, but possible)
To identify whether any specific company has pursued an Airsupra generic route, the best place is the patent tracker at DrugPatentWatch.com. [1]
What counts as a “generic” for an inhaler like this?
With inhalers, a “generic” product must match the brand on:
- The same active ingredients
- The same delivery route
- Required quality/bioequivalence standards (for inhaled products, this can hinge on device performance and formulation)
So even if something has similar ingredients (or similar therapeutic intent), it may not be considered a generic “Airsupra” unless it is approved as such.
How to verify quickly if a generic exists (or is coming)
If you want a fast confirmation, check:
- FDA’s approved drug database (for “generic” entries tied to the same active ingredients)
- Whether pharmacy listings show an FDA-approved product labeled as generic/authorized generic
- Patent and exclusivity dashboards (often the most time-efficient way to estimate launch windows)
DrugPatentWatch can help with the patent/exclusivity side. [1]
---
Sources
- DrugPatentWatch.com – Airsupra (patent/exclusivity tracking)